TRVI News and Press, Trevi Therapeutics Inc.

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic...

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (...

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) PR Newswire Statistically-s ignificant reduction in the relative change from baseline in 24-hour objective cough fr...

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference PR Newswire FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patie...

2025-12-04 07:43:18 ET More on Trevi Therapeutics Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond Trevi Therapeutics: Big Cough Data, Bigger Execution Risk Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript ...

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer PR Newswire Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, I...

2025-12-03 14:16:44 ET I'm initiating coverage of Trevi Therapeutics ( TRVI ) with a "Buy" rating, and the reason why is because it is already ahead of the game in terms of getting its lead program into phase 3 testing. I'm talking about the development of Haduvio [oral nalbuphi...

2025-12-02 16:35:03 ET More on Trevi Therapeutics Trevi Therapeutics: Big Cough Data, Bigger Execution Risk Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Confe...

2025-11-17 08:45:00 ET Introduction This is my first look at Trevi Therapeutics ( TRVI ). Data by YCharts Trevi is developing nalbuphine ER , or Haduvio, for chronic cough. Specifically, cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic ...

2025-11-14 08:15:11 ET Oppenheimer analyst issues OUTPERFORM recommendation for TRVI on November 14, 2025 11:51AM ET. The previous analyst recommendation was Outperform. TRVI was trading at $11.46 at issue of the analyst recommendation. The overall analyst consensus : BU...